Retrieve available abstracts of 28 articles: HTML format
Single Articles
June 2025
ZHANG M, Xu Z, Cao Y, Gao C, et al Analysis and characterization of extrachromosomal circular DNA in prostate
cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
Cancer Lett. 2025;628:217875. PubMedAbstract available
May 2025
JIANG H, Zeng Y, Ning W, Hong J, et al Ketogenesis instigates immune suppression in enzalutamide resistant prostate
cancer via OTUD7B beta-hydroxybutyrylation.
Cancer Lett. 2025 May 18:217808. doi: 10.1016/j.canlet.2025.217808. PubMedAbstract available
April 2025
CAI S, Deng Y, Zou Z, Tian W, et al Metformin inhibits the progression of castration resistant prostate cancer by
regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway
activation.
Cancer Lett. 2025 Apr 9:217694. doi: 10.1016/j.canlet.2025.217694. PubMedAbstract available
February 2025
CHAN HY, Wang Q, Howie A, Bucci J, et al Extracellular vesicle biomarkers redefine prostate cancer radiotherapy.
Cancer Lett. 2025 Feb 18:217568. doi: 10.1016/j.canlet.2025.217568. PubMedAbstract available
SUBRAMANIAM S, Jeet V, Gunter JH, Clements JA, et al Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug
delivery and anti-tumor efficacy in prostate cancer.
Cancer Lett. 2025 Feb 7:217522. doi: 10.1016/j.canlet.2025.217522. PubMedAbstract available
January 2025
HINDES MT, McElligott AM, Best OG, Ward MP, et al Metabolic reprogramming, malignant transformation and metastasis: lessons from
chronic lymphocytic leukaemia and prostate cancer.
Cancer Lett. 2025 Jan 2:217441. doi: 10.1016/j.canlet.2025.217441. PubMedAbstract available
November 2024
LIU R, Zou Z, Zhang Z, He H, et al Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target
and regulator of sphingosine 1-phosphate metabolism in CRPC.
Cancer Lett. 2024;605:217286. PubMedAbstract available
MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al PAF1-mediated transcriptional reprogramming confers docetaxel resistance in
advanced prostate cancer.
Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355. PubMedAbstract available
STEINER L, Eldh M, Offens A, Veerman RE, et al Protein profile in urinary extracellular vesicles is a marker of malignancy and
correlates with muscle invasiveness in urinary bladder cancer.
Cancer Lett. 2024;609:217352. PubMedAbstract available
October 2024
GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and
The Role of Circulating Tumor Cells.
Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310. PubMedAbstract available
August 2024
HE Q, Zhang Y, Li W, Chen S, et al Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but
enhances its response to immunotherapy.
Cancer Lett. 2024;602:217214. PubMedAbstract available
WANG X, Zhang L, Cheng L, Wang Y, et al Extracellular Vesicle-derived Biomarkers in Prostate Cancer Care: Opportunities
and Challenges.
Cancer Lett. 2024 Aug 12:217184. doi: 10.1016/j.canlet.2024.217184. PubMedAbstract available
LIU D, Wang L, Guo Y Advances in and Prospects of Immunotherapy for Prostate Cancer.
Cancer Lett. 2024 Aug 8:217155. doi: 10.1016/j.canlet.2024.217155. PubMedAbstract available
June 2024
LIU YN, Liu MK, Wen YC, Li CH, et al Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4
promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
Cancer Lett. 2024 Jun 28:217090. doi: 10.1016/j.canlet.2024.217090. PubMedAbstract available
CLARK A, Villarreal MR, Huang SB, Jayamohan S, et al Targeting S6K/NFkappaB/SQSTM1/Poltheta signaling to suppress radiation resistance in
Prostate Cancer.
Cancer Lett. 2024 Jun 24:217063. doi: 10.1016/j.canlet.2024.217063. PubMedAbstract available
LIU C, Chen J, Cong Y, Chen K, et al PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
Cancer Lett. 2024 Jun 18:217068. doi: 10.1016/j.canlet.2024.217068. PubMedAbstract available
CHEN HJ, Yu MM, Huang JC, Lan FY, et al SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer.
Cancer Lett. 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070. PubMedAbstract available
May 2024
KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al Diverse landscape of genetically engineered mouse models: Genomic and molecular
insights into prostate cancer.
Cancer Lett. 2024;593:216954. PubMedAbstract available
March 2024
KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al Chromatin activation with H3K36me2 and compartment shift in metastatic
castration-resistant prostate cancer.
Cancer Lett. 2024;588:216815. PubMedAbstract available
RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel
essential gene in prostate cancer metastasis.
Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776. PubMedAbstract available
February 2024
WEI Z, Zhang C, Song Y, Han D, et al CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear
translocation to suppress prostate cancer metastasis.
Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743. PubMedAbstract available
YIN W, Chen G, Li Y, Li R, et al Identification of a 9-gene signature to enhance biochemical recurrence prediction
in primary prostate cancer: A benchmarking study using ten machine learning
methods and twelve patient cohorts.
Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739. PubMedAbstract available
CHEN H, Dong K, Ding J, Xia J, et al CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI
cross-resistance in prostate cancer progression.
Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725. PubMedAbstract available
ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against
prostate cancer.
Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657. PubMedAbstract available
January 2024
SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al Dysregulation of RNA-Exosome machinery is directly linked to major cancer
hallmarks in prostate cancer: Oncogenic role of PABPN1.
Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604. PubMedAbstract available
November 2023
ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al Androgen receptor inhibition suppresses anti-tumor neutrophil response against
bone metastatic prostate cancer via regulation of TbetaRI expression.
Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468. PubMedAbstract available
October 2023
WANG C, Wang T, Li KJ, Hu LH, et al SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1
transcriptional repression and cell cycle arrest.
Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464. PubMedAbstract available
September 2023
SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al PARPing up the right tree; an overview of PARP inhibitors for metastatic
castration-resistant prostate cancer.
Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367. PubMedAbstract available